Recovery of European temperate forests after large and severe disturbances

<p><span>As climate change progresses, there is increasing concern that large and severe disturbances may diminish the resilience of forest ecosystems and alter their recovery dynamics. We investigated recovery of temperate forests in Europe following large and severe disturbance events (more than 70 % canopy cover reduction in patches larger than 1 ha) that span a time since disturbance range of one to five decades. Across a ground-based plot network at 143 sites, featuring various forest types and management practices, subjected to 28 disturbance events, including windthrow, fire, and bark beetle, we studied post-disturbance tree density and composition, which are key indicators of forest resilience. We used this dataset to qualitatively assess forest recovery in structure and composition by comparing plot-level post-disturbance height-weighted densities with site-specific pre-disturbance densities. Additionally, we analyzed ecological drivers of post-windthrow tree density, including forest management, topography, and bioclimate,  using a series of generalized additive models. The present dataset includes the plot-level data necessary to carry out the aforementioned analyses.</span></p><p>Funding provided by: Slovenian Research Agency<br>Crossref Funder Registry ID: https://ror.org/059bp8k51<br>Award Number: </p><p>Funding provided by: Estonian Research Council<br>Crossref Funder Registry ID: https://ror.org/00jjeja18<br>Award Number: </p><p>Funding provided by: Slovak Research and Development Agency<br>Crossref Funder Registry ID: http://dx.doi.org/10.13039/501100005357<br>Award Number: </p><p>Funding provided by: Czech Academy of Sciences<br>Crossref Funder Registry ID: https://ror.org/053avzc18<br>Award Number: </p><p>Funding provided by: Czech Science Foundation<br>Crossref Funder Registry ID: https://ror.org/01pv73b02<br>Award Number: </p&gt

Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy

Purpose: Proliferative vitreoretinopathy (PVR) is the major cause for surgical failure after primary rhegmatogenous retinal detachment (RRD). So far, no therapy has been proven to prevent PVR. Promising results for 5-fluorouracil (5-FU) and low-molecular weight heparin (LMWH) in high-risk eyes have been reported previously. The objective of this trial was to examine the effect of adjuvant intravitreal therapy with 5-FU and LMWH compared with placebo on incidence of PVR in high-risk patients with primary RRD. Design: Randomized, double-blind, controlled, multicenter, interventional trial with 1 interim analysis. Participants: Patients with RRD who were considered to be at high risk for PVR were included. Risk of PVR was assessed by noninvasive aqueous flare measurement using laser flare photometry. Methods: Patients were randomized 1:1 to verum (200 mg/ml 5-FU and 5 IU/ml dalteparin) and placebo (balanced salt solution) intravitreally applied during routine pars plana vitrectomy. Main Outcome Measures: Primary end point was the development of PVR grade CP (full-thickness retinal folds or subretinal strands in clock hours located posterior to equator) 1 or higher within 12 weeks after surgery. For grading, an end point committee assessed fundus photographs. Secondary end points included bestcorrected visual acuity and redetachment rate. A group sequential design with 1 interim analysis was applied using the O'Brien and Fleming boundaries. Proliferative vitreoretinopathy grade CP incidence was compared using a Mantel-Haenszel test stratified by surgeon. Results: A total of 325 patients in 13 German trial sites had been randomized (verum, n = 163; placebo, n = 162). In study eyes, mean laser flare was 31 +/- 26 pc/ms. No significant difference was found in PVR rate. Primary analysis in the modified intention-to-treat population results were: verum 28% vs. placebo 23% (including not assessable cases as failures); odds ratio [OR], 1.25; 95% confidence interval [CI], 0.76-2.08; P = 0.77. Those in the per-protocol population were: 12% vs. 12%; OR, 1.05; 95% CI, 0.47-2.34; P = 0.47. None of the secondary end points showed any significant difference between treatment groups. During the study period, no relevant safety risks were identified. Conclusions: Rate of PVR did not differ between adjuvant therapy with 5-FU and LMWH and placebo treatment in eyes with RRD. (C) 2022 by the American Academy of Ophthalmolog